GSK Aktie 119642297 / GB00BN7SWP63
18.65
CHF
0.12
CHF
0.63%
10.09.2024
BRX
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
GSK Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2023 | GSK PLC Registered Shs | 4.00 | 0.58 | GBP |
| 2022 | GSK PLC Registered Shs | 4.26 | 0.61 | GBP |
| 2021 | GSK PLC Registered Shs | 4.98 | 1.00 | GBP |
| 2020 | GSK PLC Registered Shs | 5.96 | 1.00 | GBP |
| 2019 | GSK PLC Registered Shs | 4.50 | 1.00 | GBP |
| 2018 | GSK PLC Registered Shs | 5.36 | 1.00 | GBP |
| 2017 | GSK PLC Registered Shs | 6.05 | 1.00 | GBP |
| 2016 | GSK PLC Registered Shs | 5.12 | 1.00 | GBP |
| 2015 | GSK PLC Registered Shs | 5.83 | 1.00 | GBP |
| 2014 | GSK PLC Registered Shs | 5.81 | 1.00 | GBP |
Gewinn je Aktie- GSK
| 0.4 17 | 0.9 18 | 1.2 19 | 1.4 20 | 1.1 21 | 3.7 22 | 1.2 23 |
Umsatz je Aktie- GSK
| 7.6 17 | 7.8 18 | 8.4 19 | 8.5 20 | 8.4 21 | 7.2 22 | 7.4 23 |
KGV- GSK
| 42.1 17 | 20.2 18 | 18.9 19 | 11.6 20 | 18.3 21 | 3.9 22 | 11.9 23 |
GSK PLC Registered Shs: Die Aktie (in GBP)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Ergebnis je Aktie unverwässert | 0.39 | 0.92 | 1.17 | 1.44 | 1.10 | 3.71 | 1.22 |
| Ergebnis je Aktie verwässert | 0.39 | 0.91 | 1.16 | 1.43 | 1.08 | 3.66 | 1.20 |
| Dividende pro Aktie | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.61 | 0.58 |
| Gesamtdividendenausschüttung in Mio. | 3’906.00 | 3’927.00 | 3’953.00 | 3’977.00 | 3’999.00 | 3’467.00 | 2’247.00 |
GSK PLC Registered Shs: Unternehmenskennzahlen (in GBP)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 7.64 | 7.75 | 8.41 | 8.46 | 8.42 | 7.18 | 7.38 |
| KGV (Jahresendkurs, EPS unverwässert) | 42.12 | 20.23 | 18.95 | 11.62 | 18.33 | 3.87 | 11.92 |
| KGV (Jahresendkurs, EPS verwässert) | 42.66 | 20.46 | 19.21 | 11.76 | 18.56 | 3.93 | 12.10 |
| KGV (Jahresendkurs) | 42.12 | 20.23 | 18.95 | 11.62 | 18.33 | 3.87 | 11.92 |
| Dividendenrendite Jahresende in % | 6.05 | 5.36 | 4.50 | 5.96 | 4.98 | 4.26 | 4.00 |
| Eigenkapitalquote in % | -0.12 | 7.51 | 14.31 | 18.14 | 19.03 | 17.62 | 22.62 |
| Fremdkapitalquote in % | 93.81 | 93.68 | 76.97 | 74.13 | 73.02 | 83.21 | 78.32 |
GSK PLC Registered Shs: GuV (in Mio. GBP)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 30’186.00 | 30’821.00 | 33’754.00 | 34’099.00 | 34’114.00 | 29’324.00 | 30’328.00 |
| Umsatzveränderung in % | 8.24 | 2.10 | 9.52 | 1.02 | 0.04 | -14.04 | 3.42 |
| Bruttoergebnis vom Umsatz | 20’086.00 | 20’925.00 | 22’885.00 | 23’123.00 | 22’304.00 | 19’462.00 | 21’252.00 |
| Bruttoergebnisveränderung in % | 8.94 | 4.18 | 9.37 | 1.04 | -3.54 | -12.74 | 9.20 |
| Operatives Ergebnis | 7’974.00 | 7’999.00 | 7’783.00 | 8’183.00 | 7’400.00 | 6’682.00 | 6’993.00 |
| Veränderung Operatives Ergebnis in % | 16.75 | 0.31 | -2.70 | 5.14 | -9.57 | -9.70 | 4.65 |
| Ergebnis vor Steuern | 3’512.00 | 4’769.00 | 6’147.00 | 6’935.00 | 5’409.00 | 5’630.00 | 6’069.00 |
| Veränderung Ergebnis vor Steuern in % | 81.59 | 35.79 | 28.89 | 12.82 | -22.00 | 4.09 | 7.80 |
| Ergebnis nach Steuer | 1’532.00 | 3’623.00 | 4’645.00 | 5’749.00 | 4’385.00 | 14’956.00 | 4’928.00 |
| Veränderung Ergebnis nach Steuer in % | 67.98 | 136.49 | 28.21 | 23.77 | -23.73 | 241.07 | -67.05 |
GSK PLC Registered Shs: Bilanz (in Mio. GBP)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gesamtverbindlichkeiten | 52’892 | 54’394 | 61’335 | 59’623 | 57’761 | 50’050 | 46’210 |
| Langzeit Gesamtverbindlichk. pro Aktie | 6.73 | 8.10 | 9.41 | 9.40 | 8.51 | 6.75 | 6.20 |
| Eigenkapital | 3’489 | 3’672 | 18’357 | 20’808 | 21’342 | 10’096 | 12’795 |
| Veränderung Eigenkapital in % | -106.05 | - | 161.58 | 27.90 | 3.21 | -29.60 | 25.94 |
| Bilanzsumme | 56’381 | 58’066 | 79’692 | 80’431 | 79’103 | 60’146 | 59’005 |
| Veränderung Bilanzsumme in % | -4.57 | 2.99 | 37.24 | 0.93 | -1.65 | -23.96 | -1.90 |
GSK PLC Registered Shs: Sonstige Angaben (in GBP)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | 0.39 | 0.92 | 1.17 | 1.44 | 1.10 | 3.71 | 1.22 |
| Veränderung EPS (unverwässert) in % | 67.02 | 134.80 | 27.35 | 23.05 | -24.14 | 239.07 | -67.26 |
| Gewinn je Aktie (verwässert) | 0.39 | 0.91 | 1.16 | 1.43 | 1.08 | 3.66 | 1.20 |
| Veränderung EPS (verwässert) in % | 66.67 | 135.10 | 27.07 | 23.22 | -24.13 | 238.39 | -67.27 |
| Anzahl Mitarbeiter | 98’462 | 95’490 | 99’437 | 94’066 | 90’096 | 69’400 | 70’212 |
| Veränderung Anzahl Mitarbeiter in % | -0.84 | -3.02 | 4.13 | -5.40 | -4.22 | -22.97 | 1.17 |
GSK PLC Registered Shs Termine
| Unternehmen | Event | Datum |
|---|---|---|
| GSK PLC Registered Shs | Quartalszahlen | 30.10.24 |
| GSK PLC Registered Shs | Quartalszahlen | 05.02.25 |
| GSK PLC Registered Shs | Quartalszahlen | 30.04.25 |
| GSK PLC Registered Shs | Quartalszahlen | 23.07.25 |
| GSK PLC Registered Shs | Quartalszahlen | 29.10.25 |
| GSK PLC Registered Shs | Quartalszahlen | 11.02.26 |
GSK PLC Registered Shs vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q2 2024 Earnings Release | 31.07.24 |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 92.06 |
| Government Pension Fund - Global (The) | 2.16 |
| Dodge & Cox International Stock Fund | 1.65 |
| Vanguard Total International Stock Index Fund | 1.34 |
| GlaxoSmithKline Employee Trust | 0.95 |
| Vanguard Developed Markets Index Fund | 0.82 |
| Vanguard Health Care Fund | 0.77 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 98’462 | 95’490 | 99’437 | 94’066 | 90’096 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.31 | 0.32 | 0.34 | 0.36 | 0.38 |
Bilanz (in Mio. GBP) - Aktiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 15’907 | 16’927 | 19’491 | 20’247 | 18’674 |
| Summe Anlagevermögen | 17’021 | 30’424 | 41’913 | 41’737 | 39’228 |
| Summe Aktiva | 56’381 | 58’066 | 79’692 | 80’431 | 79’103 |
Bilanz (in Mio. GBP) - Passiva
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 17’089 | 26’064 | 30’508 | 27’150 | 24’173 |
| Summe Fremdkapital | 52’892 | 54’394 | 61’335 | 59’623 | 57’761 |
| Summe Eigenkapital | 3’489 | 3’672 | 18’357 | 20’808 | 21’342 |
| Summe Passiva | 56’381 | 58’066 | 79’692 | 80’431 | 79’103 |
Adresse
| 79 New Oxford Street, WC1A 1DG London | |
| Telefon | +44 (20) 8047-5000 |
| URL | http://www.gsk.com |
Management
|
Amy Altshul
SVP-Legal, Research & Development |
|
Anita Kidgell
Senior Vice President-Corporate Strategy |
|
Anne C. Beal
Independent Non-Executive Director |
|
Anne-Marie Martin
Senior VP & Global Head-Experimental Medicine Unit |
|
Carlo Russo
Head-Development R&D Biopharm |
|
Charles A. Bancroft
Senior Independent Non-Executive Director |
|
Christopher Corsico
Senior Vice President-Development |
|
Claire Lund
Head-Environmental Sustainability |
|
David Simon Redfern
President-Corporate Development |
|
Diana Conrad
Chief People Officer |
|
Elizabeth McKee Anderson
Independent Non-Executive Director |
|
Emma N. Walmsley
Chief Executive Officer & Executive Director |
|
Frannie DeFranco
Director-Philadelphia Investor Relations |
|
Graham Rivers
Vice President & Financial Controller |
|
Hal V. Barron
Non-Independent Non-Executive Director |
|
Harry C. Dietz
Independent Non-Executive Director |
|
James Ford
Group General Counsel, Head-Legal & Compliance |
|
Jeannie T. Lee
Non-Executive Director |
|
Jesse L. Goodman
Independent Non-Executive Director |
|
Jonathan Richard Symonds
Non-Executive Chairman |
|
Julie Brown
Chief Financial Officer & Executive Director |
|
Luke Miels
Chief Commercial Officer |
|
María Cristina de Luna Basagoiti
General Manager-Spain |
|
Maya Martinez-Davis
President-US Pharmaceuticals |
|
Michael Elmore
Senior Vice President |
|
Mick John Readey
Investor Relations Contact |
|
Philip Thomson
President-Global Affairs |
|
Regis Jean-Pierre Simard
President-Global Supply Chain |
|
Shobie Ramakrishnan
Chief Digital & Technology Officer |
|
Sonya Ghobrial
Head-Consumer Healthcare Investor Relations |
|
Timothy Woodthorpe
Group Treasurer & Senior Vice President |
|
Tony Wood
Chief Scientific Officer |
|
Victoria A. Whyte
Secretary |
|
Vishal Sikka
Independent Non-Executive Director |
|
Wendy Becker
Non-Executive Director |